Hepatic steatosis: effect on hepatocyte enhancement with gadoxetate disodium-enhanced liver MR imaging.
To investigate the effect of hepatic steatosis on enhancement of liver parenchyma with gadoxetate disodium-enhanced MR imaging. Gadoxetate disodium-enhanced MR images of 166 patients were analyzed. Liver-spleen contrast and liver-spleen relative enhancement ratio on three-dimensional gradient echo T1-weighted images with fat suppression 20 minutes after injection of gadoxetate disodium were evaluated in correlation with fat signal fraction using the Pearson correlation coefficient and also compared between patients with normal liver parenchyma (n = 115) and with liver steatosis (n = 51) using the Student t-test. The liver-spleen contrast at hepatobiliary phase showed inverse correlations with the fat signal fraction (r = -0.36; P < 0.01), while the liver-spleen relative enhancement ratio showed no statistical correlation with the fat signal fraction (P = 0.80). The liver-spleen contrast in the group with steatotic liver was significantly lower than that in the group with normal livers (P < 0.001). There was no significant difference in the relative enhancement ratio between the two groups (P = 0.85). Our results may suggest that hepatic steatosis does not affect the uptake of gadoxetate disodium into hepatocytes and are considered crucial as background knowledge in extending the use of gadoxetate disodium-enhanced MR imaging to quantitate liver function.